Efficacy and Safety of Tranexamic Acid Administration in Patients with Acute Traumatic Brain Injury: A Review of Current Literature

Vol 8 | Issue 2 | July-December 2022 | page: 01-07 | Kenzie Kao, Mohammed Alsabri

DOI: 10.13107/ti.2022.v08i02.028


Authors: Kenzie Kao [1], Mohammed Alsabri [2]

[1] Saba University School of Medicine, Saba, Dutch Caribbean, Netherlands. [2] Department of Emergency Medicine, Al-Thawra Modern General Teaching Hospital, Sana’a City, Yemen. Address of Correspondence Dr. Mohammed Alsabri, Department of Emergency Medicine, Al-Thawra Modern General Teaching Hospital, Sana’a City, Yemen. E-mail: alsabri5000@gmail.com


Abstract

Hypothesis: Early administration of tranexamic acid (TXA) reduces mortality in patients suffering from acute traumatic brain injury (TBI). Methods: A structured search of PubMed and CENTRAL from inception until July 1st, 2022 was carried out seeking RCTs comparing the effects of TXA administration to placebo in patients suffering from TBI. The primary outcome tested was 28-day all-cause mortality. Secondary outcomes included intracranial hemorrhage growth and thromboembolic events. Results: Eight RCTs involving a total of 14,714 patients met the inclusion criteria; 7573 patients received TXA while 7141 patients received a placebo. There were 1415 patient deaths (18.7%) in the TXA group and 1410 patient deaths (19.7%) in the placebo group. None of the included studies reported a significant reduction in 28-day all-cause mortality, however, they all shared positive trends toward superior outcomes in the intervention arms. Two of the included studies reported significant reductions in intracranial hemorrhage expansion in those patients treated with TXA, with four more studies reporting trends toward superior outcomes in the TXA groups. There was no evidence of increased incidence of thromboembolic events in the TXA groups in four of the five studies that reported relevant data, with one study representing 1.2% of total patients reporting an increased incidence of pulmonary emboli in the intervention group. Conclusions: In patients suffering from acute TBI, early administration of TXA reduces intracranial hemorrhage growth and may have positive effects on mortality with no corresponding increase in thromboembolic events. Given these results, early administration of TXA in patients experiencing TBI is recommended in initial care. Keywords: Tranexamic acid, Traumatic brain injury, Intracranial hemorrhage, Mortality, Disability


References

1) Dewan, M. C., Rattani, A., Gupta, S., Baticulon, R. E., Hung, Y. C., Punchak, M., Agrawal, A., Adeleye, A. O., Shrime, M. G., Rubiano, A. M., Rosenfeld, J. V., & Park, K. B. (2018). Estimating the global incidence of traumatic brain injury. Journal of neurosurgery, 1–18. Advance online publication. https://doi.org/10.3171/2017.10.JNS17352 2) Maas, A., Menon, D. K., Adelson, P. D., Andelic, N., Bell, M. J., Belli, A., Bragge, P., Brazinova, A., Büki, A., Chesnut, R. M., Citerio, G., Coburn, M., Cooper, D. J., Crowder, A. T., Czeiter, E., Czosnyka, M., Diaz-Arrastia, R., Dreier, J. P., Duhaime, A. C., Ercole, A., … InTBIR Participants and Investigators (2017). Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research. The Lancet. Neurology, 16(12), 987–1048. https://doi.org/10.1016/S1474-4422(17)30371-X 3) Zhang, J., Zhang, F., & Dong, J. F. (2018). Coagulopathy induced by traumatic brain injury: systemic manifestation of a localized injury. Blood, 131(18), 2001–2006. https://doi.org/10.1182/blood-2017-11-784108 4) Nakae, R., Takayama, Y., Kuwamoto, K., Naoe, Y., Sato, H., & Yokota, H. (2016). Time Course of Coagulation and Fibrinolytic Parameters in Patients with Traumatic Brain Injury. Journal of neurotrauma, 33(7), 688–695. https://doi.org/10.1089/neu.2015.4039 5) Perel, P., Edwards, P., Shakur, H., & Roberts, I. (2008). Use of the Oxford Handicap Scale at hospital discharge to predict Glasgow Outcome Scale at 6 months in patients with traumatic brain injury. BMC medical research methodology, 8, 72. https://doi.org/10.1186/1471-2288-8-72 6) Taam, J., Yang, Q. J., Pang, K. S., Karanicolas, P., Choi, S., Wasowicz, M., & Jerath, A. (2020). Current Evidence and Future Directions of Tranexamic Acid Use, Efficacy, and Dosing for Major Surgical Procedures. Journal of cardiothoracic and vascular anesthesia, 34(3), 782–790. https://doi.org/10.1053/j.jvca.2019.06.042 7) CRASH-2 trial collaborators, Shakur, H., Roberts, I., Bautista, R., Caballero, J., Coats, T., Dewan, Y., El-Sayed, H., Gogichaishvili, T., Gupta, S., Herrera, J., Hunt, B., Iribhogbe, P., Izurieta, M., Khamis, H., Komolafe, E., Marrero, M. A., Mejía-Mantilla, J., Miranda, J., Morales, C., … Yutthakasemsunt, S. (2010). Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet (London, England), 376(9734), 23–32. https://doi.org/10.1016/S0140-6736(10)60835-5 8) Bennett, C., Klingenberg, S. L., Langholz, E., & Gluud, L. L. (2014). Tranexamic acid for upper gastrointestinal bleeding. The Cochrane database of systematic reviews, 2014(11), CD006640. https://doi.org/10.1002/14651858.CD006640.pub3 9) Ker, K., Edwards, P., Perel, P., Shakur, H., & Roberts, I. (2012). Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ (Clinical research ed.), 344, e3054. https://doi.org/10.1136/bmj.e3054 10) WOMAN Trial Collaborators (2017). Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet (London, England), 389(10084), 2105–2116. https://doi.org/10.1016/S0140-6736(17)30638-4 11) Diaz-Arrastia, R., Kochanek, P. M., Bergold, P., Kenney, K., Marx, C. E., Grimes, C. J., Loh, L. T., Adam, L. T., Oskvig, D., Curley, K. C., & Salzer, W. (2014). Pharmacotherapy of traumatic brain injury: state of the science and the road forward: report of the Department of Defense Neurotrauma Pharmacology Workgroup. Journal of neurotrauma, 31(2), 135–158. https://doi.org/10.1089/neu.2013.3019 12) CRASH-3 trial collaborators (2019). Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. Lancet (London, England), 394(10210), 1713–1723. https://doi.org/10.1016/S0140-6736(19)32233-0 13) Rowell, S. E., Meier, E. N., McKnight, B., Kannas, D., May, S., Sheehan, K., Bulger, E. M., Idris, A. H., Christenson, J., Morrison, L. J., Frascone, R. J., Bosarge, P. L., Colella, M. R., Johannigman, J., Cotton, B. A., Callum, J., McMullan, J., Dries, D. J., Tibbs, B., Richmond, N. J., … Schreiber, M. A. (2020). Effect of Out-of-Hospital Tranexamic Acid vs Placebo on 6-Month Functional Neurologic Outcomes in Patients With Moderate or Severe Traumatic Brain Injury. JAMA, 324(10), 961–974. https://doi.org/10.1001/jama.2020.8958 14) CRASH-2 Collaborators, Intracranial Bleeding Study (2011). Effect of tranexamic acid in traumatic brain injury: a nested randomised, placebo controlled trial (CRASH-2 Intracranial Bleeding Study). BMJ (Clinical research ed.), 343, d3795. https://doi.org/10.1136/bmj.d3795 15) Yutthakasemsunt, S., Kittiwatanagul, W., Piyavechvirat, P., Thinkamrop, B., Phuenpathom, N., & Lumbiganon, P. (2013). Tranexamic acid for patients with traumatic brain injury: a randomized, double-blinded, placebo-controlled trial. BMC emergency medicine, 13, 20. https://doi.org/10.1186/1471-227X-13-20 16) Fakharian, E., Abedzadeh-Kalahroudi, M., & Atoof, F. (2018). Effect of Tranexamic Acid on Prevention of Hemorrhagic Mass Growth in Patients with Traumatic Brain Injury. World neurosurgery, 109, e748–e753. https://doi.org/10.1016/j.wneu.2017.10.075 17) Chakroun-Walha, O., Samet, A., Jerbi, M., Nasri, A., Talbi, A., Kanoun, H., Souissi, B., Chtara, K., Bouaziz, M., Ksibi, H., & Rekik, N. (2019). Benefits of the tranexamic acid in head trauma with no extracranial bleeding: a prospective follow-up of 180 patients. European journal of trauma and emergency surgery : official publication of the European Trauma Society, 45(4), 719–726. https://doi.org/10.1007/s00068-018-0974-z 18) Jokar, A., Ahmadi, K., Salehi, T., Sharif-Alhoseini, M., & Rahimi-Movaghar, V. (2017). The effect of tranexamic acid in traumatic brain injury: A randomized controlled trial. Chinese journal of traumatology = Zhonghua chuang shang za zhi, 20(1), 49–51. https://doi.org/10.1016/j.cjtee.2016.02.005 19) Safari, H., Farrahi, P., Rasras, S., Marandi, H. J., & Zeinali, M. (2021). Effect of Intravenous Tranexamic Acid on Intracerebral Brain Hemorrhage in Traumatic Brain Injury. Turkish neurosurgery, 31(2), 223–227. https://doi.org/10.5137/1019-5149.JTN.30774-20.4 20) Beez, T., Steiger, H. J., & Etminan, N. (2017). Pharmacological targeting of secondary brain damage following ischemic or hemorrhagic stroke, traumatic brain injury, and bacterial meningitis – a systematic review and meta-analysis. BMC neurology, 17(1), 209. https://doi.org/10.1186/s12883-017-0994-z 21) Morrison, J. J., Dubose, J. J., Rasmussen, T. E., & Midwinter, M. J. (2012). Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) Study. Archives of surgery (Chicago, Ill. : 1960), 147(2), 113–119. https://doi.org/10.1001/archsurg.2011.287 22) Gayet-Ageron, A., Prieto-Merino, D., Ker, K., Shakur, H., Ageron, F. X., Roberts, I., & Antifibrinolytic Trials Collaboration (2018). Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage: a meta-analysis of individual patient-level data from 40 138 bleeding patients. Lancet (London, England), 391(10116), 125–132. https://doi.org/10.1016/S0140-6736(17)32455-8 23) Fletcher-Sandersjöö, A., Thelin, E. P., Maegele, M., Svensson, M., & Bellander, B. M. (2021). Time Course of Hemostatic Disruptions After Traumatic Brain Injury: A Systematic Review of the Literature. Neurocritical care, 34(2), 635–656. https://doi.org/10.1007/s12028-020-01037-8 24) Capizzi, A., Woo, J., & Verduzco-Gutierrez, M. (2020). Traumatic Brain Injury: An Overview of Epidemiology, Pathophysiology, and Medical Management. The Medical clinics of North America, 104(2), 213–238. https://doi.org/10.1016/j.mcna.2019.11.001 25) Reith, F., Lingsma, H. F., Gabbe, B. J., Lecky, F. E., Roberts, I., & Maas, A. (2017). Differential effects of the Glasgow Coma Scale Score and its Components: An analysis of 54,069 patients with traumatic brain injury. Injury, 48(9), 1932–1943. https://doi.org/10.1016/j.injury.2017.05.038 26) Lawati, K. A., Sharif, S., Maqbali, S. A., Rimawi, H. A., Petrosoniak, A., Belley-Cote, E. P., Sharma, S. V., Morgenstern, J., Fernando, S. M., Owen, J. J., Zeller, M., Quinlan, D., Alhazzani, W., & Rochwerg, B. (2021). Efficacy and safety of tranexamic acid in acute traumatic brain injury: a systematic review and meta-analysis of randomized-controlled trials. Intensive care medicine, 47(1), 14–27. https://doi.org/10.1007/s00134-020-06279-w 27) Brenner, A., Arribas, M., Cuzick, J., Jairath, V., Stanworth, S., Ker, K., Shakur-Still, H., & Roberts, I. (2018). Outcome measures in clinical trials of treatments for acute severe haemorrhage. Trials, 19(1), 533. https://doi.org/10.1186/s13063-018-2900-4 28) Brenner, A., Belli, A., Chaudhri, R., Coats, T., Frimley, L., Jamaluddin, S. F., Jooma, R., Mansukhani, R., Sandercock, P., Shakur-Still, H., Shokunbi, T., Roberts, I., & CRASH-3 trial collaborators (2020). Understanding the neuroprotective effect of tranexamic acid: an exploratory analysis of the CRASH-3 randomised trial. Critical care (London, England), 24(1), 560. https://doi.org/10.1186/s13054-020-03243-4 29) Yokobori, S., Yatabe, T., Kondo, Y., Kinoshita, K., & Japan Resuscitation Council (JRC) Neuroresuscitation Task Force and the Guidelines Editorial Committee (2020). Efficacy and safety of tranexamic acid administration in traumatic brain injury patients: a systematic review and meta-analysis. Journal of intensive care, 8, 46. https://doi.org/10.1186/s40560-020-00460-5 30) Du, C. N., Liu, B. X., Ma, Q. F., & Yang, M. F. (2020). The effect of tranexamic acid in patients with TBI: a systematic review and meta-analysis of randomized controlled trials. Chinese neurosurgical journal, 6, 14. https://doi.org/10.1186/s41016-020-00196-z 31) CRASH-3 Intracranial Bleeding Mechanistic Study Collaborators (2021). Tranexamic acid in traumatic brain injury: an explanatory study nested within the CRASH-3 trial. European journal of trauma and emergency surgery : official publication of the European Trauma Society, 47(1), 261–268. https://doi.org/10.1007/s00068-020-01316-1 32) Taam, J., Yang, Q. J., Pang, K. S., Karanicolas, P., Choi, S., Wasowicz, M., & Jerath, A. (2020). Current Evidence and Future Directions of Tranexamic Acid Use, Efficacy, and Dosing for Major Surgical Procedures. Journal of cardiothoracic and vascular anesthesia, 34(3), 782–790. https://doi.org/10.1053/j.jvca.2019.06.042 33) Guerriero, C., Cairns, J., Perel, P., Shakur, H., Roberts, I., & CRASH 2 trial collaborators (2011). Cost-effectiveness analysis of administering tranexamic acid to bleeding trauma patients using evidence from the CRASH-2 trial. PloS one, 6(5), e18987. https://doi.org/10.1371/journal.pone.0018987 34) Williams, J., Roberts, I., Shakur-Still, H., Lecky, F. E., Chaudhri, R., & Miners, A. (2020). Cost-effectiveness analysis of tranexamic acid for the treatment of traumatic brain injury, based on the results of the CRASH-3 randomised trial: a decision modelling approach. BMJ global health, 5(9), e002716. https://doi.org/10.1136/bmjgh-2020-002716


How to Cite this article: Kao K, Alsabri M | Efficacy and Safety of Tranexamic Acid Administration in Patients with Acute Traumatic Brain Injury: A Review of Current Literature | July-December 2022; 8(2): 01-07.

 


(Abstract Text HTML)   (Download PDF)